Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Squamous Non-small-cell Lung Cancer × Gemcitabine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Pancreatic Neoplasms 182 Carcinoma, Non-Small-Cell Lung 113 Neoplasms 89 Neoplasm Metastasis 63 Breast Neoplasms 61 Urinary Bladder Neoplasms 33 Ovarian Neoplasms 31 Lung Neoplasms 30 Triple Negative Breast Neoplasms 29 Colorectal Neoplasms 27 Cholangiocarcinoma 26 Lymphoma, Large B-Cell, Diffuse 25 Biliary Tract Neoplasms 24 Adenocarcinoma 22 Recurrence 18 Carcinoma, Transitional Cell 18 Lymphoma, Non-Hodgkin 17 Lymphoma 17 Parkinson Disease 4, Autosomal Dominant Lewy Body 14 Fallopian Tube Neoplasms 14 Carcinoma, Pancreatic Ductal 13 Stomach Neoplasms 12 Non-Muscle Invasive Bladder Neoplasms 12 Gallbladder Neoplasms 12 Sarcoma 11 Nasopharyngeal Carcinoma 11 Bile Duct Neoplasms 11 Carcinoma 10 Solid Tumors 9 Melanoma 8

Interventions

Gemcitabine 1 Cisplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02996214 2020-02-13

LIPUSU

Nanjing Luye Sike Pharmaceutical Co., Ltd.

Phase 4 Unknown

Squamous Non-small-cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡